WEBULL
WebtradeDownload

Omega Healthcare Investors (OHI) Could Be 9% Below Fair Value Following The Latest Fed Move

Simply Wall St · 2d ago

Why the latest Fed move puts Omega Healthcare Investors back in focus

The Federal Reserve’s decision to lift rates to 3.75 to 4.0% after a long pause has pulled investor attention toward steady income payers. Omega Healthcare Investors (OHI) now sits squarely in that conversation.

Recent trading suggests investors are leaning back toward Omega Healthcare Investors, with the share price at US$47.37 and a 90 day share price return of 6.38%. Over the longer run, the 5 year total shareholder return of 123.05% indicates that momentum has favoured patient holders even through rate shifts.

Spot 6 dividend fortresses that, like Omega Healthcare Investors, put dependable income and cash coverage at the center of their appeal as rates stay higher for longer.

After a 20.4% one year total return and a share price near US$47, the question sharpens: Does Omega Healthcare Investors still offer a fair trade off between income, growth prospects and risk at this level?

Most Popular Narrative: 9% Undervalued

On the most followed view of Omega Healthcare Investors, a fair value of $51.94 sits above the recent $47.37 close. This frames the current debate around how durable its cash flows really are in a higher rate world.

Omega's disciplined balance sheet management and opportunistic use of both debt and equity (with a low leverage ratio at decade lows and largely fixed-rate debt) position the company to pursue high-yield acquisitions and portfolio expansion at accretive rates, supporting long-term AFFO and net earnings growth.

See why 54 investors see Omega Healthcare Investors as 9% undervalued.

Based on that narrative, investors are effectively being asked to accept a discount rate of 7.36% and a fair value mark that is about 9% above where Omega Healthcare Investors currently trades. The gap is not huge, but it reflects a belief that tenant health, sector demand and disciplined capital deployment can offset forecasts that show annual revenue dipping 1.7% and earnings easing from $842.0m to $711.4m by 2029.

Analysts backing this view also assume profit margins settle near 59.5%, down from 66.8% today, and that the share count grows roughly 2.7% per year. Those inputs still produce a fair value of $51.94 when discounted at 7.36%, but only if Omega Healthcare Investors eventually commands a P/E of about 29.7x on 2029 earnings, compared with 17.6x implied today and below the 34.2x multiple cited for the broader US Health Care REIT group in the narrative.

The narrative does not treat that higher future multiple as a stretch, largely because Omega Healthcare Investors screens as good value on several checks, carries a 5.74% dividend yield flagged as high and reliable, and has grown earnings 12.8% per year over five years with a sharp 84.9% jump in the last twelve months that reflects both operational progress and a $274.8m one off gain. Set against that, forecasts call for earnings to decline about 7.9% a year over the next three years and for revenue to edge down, while leverage is described as high and returns on equity are expected to settle near 10.9%, which the framework considers low.

Result: Fair Value of $51.94 (UNDERVALUED)

Still, tenant credit setbacks such as the Genesis bankruptcy and any future cuts to Medicare or Medicaid reimbursements could quickly challenge that 9% undervalued narrative.

Find out about the key risks to this Omega Healthcare Investors narrative.

Next Steps

Plenty in this Omega Healthcare Investors story points both ways. Move quickly on your own homework and weigh the 4 key rewards and 3 important warning signs.

Looking for more Omega Healthcare Investors style ideas?

If Omega Healthcare Investors has sharpened your focus on income, quality and risk, use the Simply Wall Street screener to uncover a wider field of potential candidates.

  • Target resilience first by scanning a 11 resilient stocks with low risk scores that can help you line up businesses where balance sheets and risk scores work in your favour.
  • Hunt for pricing gaps with the 29 high quality undervalued stocks, so you can shortlist companies where fundamentals and valuation screens point in the same direction.
  • Build a payout focused watchlist using the 6 dividend fortresses, and keep track of high yielding businesses that still clear key quality and coverage checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.